IGA NEPHROPATHY (IGAN)

This study is testing if starting a special, targeted-release steroid capsule called budesonide early can help control IgA nephropathy, a kidney disease. It will involve 200 adults recently diagnosed with the condition to see if the treatment safely reduces protein in their urine…

This early-stage study is testing a new cell therapy called GT719 in adults with several types of immune-mediated kidney diseases that have not responded well to standard treatments. The main goals are to find a safe dose and see how well the body tolerates the treatment, while a…

This early-stage study is testing the safety and initial effects of a new type of cell therapy for people with severe autoimmune diseases that haven't responded well to standard treatments. The therapy, called 'universal' CAR-T, uses donated immune cells engineered to target and …

This study is testing whether an experimental tablet called HSK39297 can help control IgA nephropathy, a kidney disease. About 370 adults with confirmed IgA nephropathy will take either the real tablet or a placebo for up to two years. Researchers will measure how well the drug r…

This study is testing an experimental drug called ADX-038 for people with specific immune-related kidney diseases. Researchers will enroll 45 adults with conditions like IgA nephropathy or C3 glomerulopathy to see if the drug is safe and helps control their kidney disease. The go…

This study is testing whether a drug called avacopan, given with a low dose of steroids, can help control a serious, fast-progressing form of kidney disease called crescentic IgA nephropathy. It will involve 16 adults with this condition to see if the treatment safely reduces pro…

This study is testing an investigational injection called RG002C0106 for adults with IgA nephropathy, a kidney disease. It aims to see if the treatment safely reduces protein in the urine and helps protect kidney function over 24 weeks. The trial will involve about 30 participant…